3654 results for «600»

Filter By

3654 results

Coronary interventions: first-in-man and novel devices

20 May 2026 – From EuroPCR 2026

Explore pioneering advancements in coronary interventions with first-in-man and novel devices. This session presents groundbreaking studies including cryotherapy for vulnerable plaques, a novel intravascular crossing system for coronary CTOs, sirolimus-coated retrievable scaffold therapy for in-stent restenosis, real-time intravascular photoacoustic imaging of lipid-rich plaques, and the inaugural...

Complex left main patients and PCI

20 May 2026 – From EuroPCR 2026

This session addressed the complexities of left main PCI, focusing on managing hemodynamic uncertainty in high-risk interventions, advanced techniques such as ultra-low contrast rota-tripsy PCI, precise stent positioning, and pragmatic approaches to CHIP cases, emphasizing contrast-sparing strategies and best practice balancing.

Multi-device approach to calcified lesions

20 May 2026 – From EuroPCR 2026

Explore a multi-device strategy for tackling complex calcified coronary lesions in this session. It includes case studies on left main trifurcation stenting, resistant calcified nodules treated with orbital atherectomy, severe restenosis, and critical calcifications in challenging anatomies, showcasing advanced techniques for plaque modification and lesion management.

TAVI for aortic regurgitation

20 May 2026 – From EuroPCR 2026

This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.

When transfemoral is not an option: is TAVI still possible?

20 May 2026 – From EuroPCR 2026

This session explores alternative access strategies for Transcatheter Aortic Valve Implantation (TAVI) when the transfemoral route is not feasible. It covers complex scenarios including transcaval TAVI complications, transaxillary approaches, management of extra-large annuli with peripheral artery disease, and innovative transcarotid valve-in-valve procedures.

Imaging and physiology-guided DCB strategy

20 May 2026 – From EuroPCR 2026

Delve into advanced imaging and physiology-guided drug-coated balloon (DCB) strategies for complex coronary lesions. This session presents integrated approaches combining morphology and physiology, OCT guidance, and real-world cases highlighting DCB use in multivessel disease and calcified lesions.

CTO PCI in images and case examples: what is new in 2026?

07 Jul 2026

Register for free to this webinar on Monday 31 August at 6:00pm with K. Mashayekhi, M. Ayoub and C. Ungureanu and learn to review the recent evidence on expected outcomes after CTO PCI, and much more!

CTO PCI in images and case examples: what is new in 2026?

Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)

27 Oct 2023

Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)

The greatest advance in the next 40 years would be to remove the need for angioplasty

17 May 2017

Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...

Authors :

Spencer B. King
Spencer B. King

ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI

28 Mar 2026

Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide percutaneous coronary intervention

COVID-19 vaccines: Burning questions from the community and real-world applicability

13 Jan 2021

View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.

COVID-19 vaccines: Burning questions from the community and real-world applicability

A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial

03 Apr 2026

Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...

John Davies

Author

John Davies
Kalaivani Mahadevan

Author

Kalaivani Mahadevan
Sarosh Khan

Author

Sarosh Khan
ORBITA-CTO: Chronic total occlusion PCI in stable angina

From PROTECT-AF to CHAMPION-AF: Where do we stand today?

01 Jul 2026

In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.

Jens-Erik-Nielsen-Kudsk

Author

Jens Erik Nielsen-Kudsk
From PROTECT-AF to CHAMPION-AF: Where do we stand today?

The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation

01 Sep 2025

Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.

Author

Chiara De Biase
The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]
Didn’t find what you were looking for?